FDA Clears Expanded Access Programme for StemCyte's RegeneCyte Therapy in Long covid Patients
The FDA has approved an Expanded Access programme for StemCyte’s RegeneCyte, enabling eligible Long covid patients to access the cord blood-based therapy amid ongoing clinical trials.
Expanded Access Programme | 27/01/2026 | By News Bureau | 107
EMA Recommends EU Approval for Waskyra to Treat Wiskott-Aldrich Syndrome
The EMA has recommended EU marketing authorisation for Waskyra (etuvetidigene autotemcel), a gene therapy for patients aged six months and older with Wiskott-Aldrich Syndrome (WAS). The treatment uses a patient’s own modified stem cells to restore functional WAS protein.
Expanded Access Programme | 17/11/2025 | By Dineshwori | 156
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy